ATE225670T1 - Antagonistische anti-avb3 integrin antikörper - Google Patents

Antagonistische anti-avb3 integrin antikörper

Info

Publication number
ATE225670T1
ATE225670T1 AT98915334T AT98915334T ATE225670T1 AT E225670 T1 ATE225670 T1 AT E225670T1 AT 98915334 T AT98915334 T AT 98915334T AT 98915334 T AT98915334 T AT 98915334T AT E225670 T1 ATE225670 T1 AT E225670T1
Authority
AT
Austria
Prior art keywords
integrin antibodies
antagonistic anti
avb3 integrin
avb3
integrin
Prior art date
Application number
AT98915334T
Other languages
English (en)
Inventor
Christopher P Carron
Debra M Meyer
G Allen Nickols
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE225670T1 publication Critical patent/ATE225670T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT98915334T 1997-04-11 1998-04-09 Antagonistische anti-avb3 integrin antikörper ATE225670T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4385397P 1997-04-11 1997-04-11
PCT/US1998/006867 WO1998046264A1 (en) 1997-04-11 1998-04-09 Antagonistic anti-avb3 integrin antibodies

Publications (1)

Publication Number Publication Date
ATE225670T1 true ATE225670T1 (de) 2002-10-15

Family

ID=21929212

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98915334T ATE225670T1 (de) 1997-04-11 1998-04-09 Antagonistische anti-avb3 integrin antikörper

Country Status (11)

Country Link
US (1) US6171588B1 (de)
EP (1) EP0973550B1 (de)
JP (1) JP2001521520A (de)
AT (1) ATE225670T1 (de)
AU (1) AU6954398A (de)
CA (1) CA2284726A1 (de)
DE (1) DE69808609T2 (de)
DK (1) DK0973550T3 (de)
ES (1) ES2187954T3 (de)
PT (1) PT973550E (de)
WO (1) WO1998046264A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1071468B1 (de) * 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
HUP0300868A3 (en) * 2000-06-29 2005-11-28 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20030082103A1 (en) * 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
US20020197210A1 (en) * 2001-03-08 2002-12-26 Bednarski Mark David Stabilized therapeutic and imaging agents
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
KR100861466B1 (ko) * 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
HUP0400284A3 (en) 2001-05-03 2012-09-28 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
CN1606566A (zh) * 2001-10-22 2005-04-13 斯克里普斯研究学院 整联蛋白靶向化合物
US7186804B2 (en) * 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
BR0307206A (pt) 2002-01-24 2004-12-21 Barnes Jewish Hospital Agentes de formação de imagem direcionados por integrina
AU2003217930A1 (en) * 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP1487489A4 (de) * 2002-03-04 2008-10-01 Medimmune Inc VERFAHREN ZUR PRÄVENTION ODER BEHANDLUNG VON ERKRANKUNGEN DURCH VERABREICHUNG EINES INTEGRIN avb3 ANTAGONISTEN IN KOMBINATION MIT EINEM HMG-CoA REDUKTASE-HEMMER ODER EINEM BISPHOSPHONAT
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
WO2004016733A2 (en) * 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
DK1572748T3 (da) * 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
SG129272A1 (en) * 2003-01-22 2007-02-26 Univ Singapore Molecules, compositions, methods and kits for applications associated with flaviviruses
JP2006516635A (ja) * 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストの使用
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
JP2010500360A (ja) 2006-08-10 2010-01-07 アルボア コーポレーション 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法
KR101405440B1 (ko) 2012-07-31 2014-06-20 연세대학교 산학협력단 인테그린αｖβ３에 특이적 압타머 및 이의 용도
MA45408A (fr) 2016-06-17 2019-04-24 Magenta Therapeutics Inc Compositions et procédés pour la déplétion des cellules cd117+
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
WO2021015336A1 (ko) * 2019-07-24 2021-01-28 가톨릭대학교 산학협력단 αVβ3 인테그린 표적 단일 도메인 항체

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4965392A (en) 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US5591829A (en) 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US5306620A (en) 1987-07-08 1994-04-26 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
WO1989005155A1 (en) * 1987-11-19 1989-06-15 Scripps Clinic And Research Foundation Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells
US5057604A (en) 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5149780A (en) 1988-10-03 1992-09-22 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0832980B1 (de) 1989-01-23 2002-06-19 Chiron Corporation Rekombinanttherapien für Infektionen und hyperproliferative Störungen
JP3093383B2 (ja) 1990-11-30 2000-10-03 塩野義製薬株式会社 抗体標識のための放射性ヨウ素化合物
JP3353209B2 (ja) 1992-04-03 2002-12-03 ジェネンテク，インコーポレイテッド αｖβ３インテグリンに対する抗体
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
JP2001521520A (ja) 2001-11-06
AU6954398A (en) 1998-11-11
US6171588B1 (en) 2001-01-09
WO1998046264A1 (en) 1998-10-22
DK0973550T3 (da) 2003-02-10
DE69808609T2 (de) 2003-06-12
EP0973550A1 (de) 2000-01-26
ES2187954T3 (es) 2003-06-16
DE69808609D1 (de) 2002-11-14
EP0973550B1 (de) 2002-10-09
PT973550E (pt) 2003-01-31
CA2284726A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
DK0973550T3 (da) Antagonistiske anti-AVB3-integrin-antistoffer
TR199501614A2 (tr) Anti-alfa integrin monoklonal antikor.
RS53984B1 (en) IP-10 ANTIBODIES AND THEIR USES
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
IL154326A0 (en) Anti-dual integrin antibodies, compositions, methods and uses
EE200100336A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
EE201200006A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
NO924279D0 (no) Lyofilisert, monoklonalt antistoffpreparat
DE69829891D1 (de) Anti-VEGF Antikörper
DK0724456T3 (da) CD40-Antistoffer
IL147517A0 (en) Monoclonal antibodies and immunoassay utilizing the same
PL330842A1 (en) Purified superficial sperm antigen, monoclonal antibody therefor and applications associated therewith
ATE476989T1 (de) Humanisierter monoklonaler antikörper gegen von- willebrand faktor
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69738312D1 (de) Hepatitis b monoklonale antikörper
HUP0103152A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
TR199800517A3 (tr) Hümanize anti-hümen fas antikor.
BR0015872A (pt) Agentes antitrombóticos
EP0759943A4 (de) Monoklonale antikörper spezifisch gegen vaskuläres endothelzellartigen endoglyx-1, das antigen selbst und seine verwendungen
NO20004251D0 (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
ATE293685T1 (de) Monoklonaler antikörper gegen ratte beta-2- integrin alpha d untereinheit und entsprechendes hybridoma
NO890116L (no) Monoklonale antistoffer.
DE69023717D1 (de) Monoklonaler Antikörper.
BR1100555B1 (pt) anticorpos monoclonais humanizados.
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0973550

Country of ref document: EP

REN Ceased due to non-payment of the annual fee